Role summary
-
Provide technical leadership within Manufacturing Science and Technology by defining and maintaining the processes as part of Tech transfer / NPI activities such as,
-
ICH-Q3 risk assessments and testing strategies
-
Establishment of an end‑to‑end process for materials management (raw materials, process consumables, single‑use components).
-
Translate GMP and regulatory expectations into robust risk management strategies, ensuring compliance and reliable manufacturing & supply.
Key responsibilities
Lead and author ICH Q3 risk assessments:
-
Perform risk identification, quantification, and control strategy definition for process‑related impurities derived from materials of construction of product contact materials.
-
Define and justify risk monitoring testing strategies using ICH Q9 principles and product knowledge.
Lead process materials management:
-
Own the lifecycle of process materials from specification through qualification, use, and change control.
-
Establish material requirements and critical attributes; create critical materials qualification protocols and reports i.e for single use systems (SUS).
-
Implement whenever necessary dual sourcing or alternate materials, and identify obsolescence risks
Technical stewardship and investigations:
-
Lead material- or impurity-related deviations, root cause analyses, and CAPAs.
-
Trend process related impurities and selected material quality attributes; build predictive monitoring and alert limits for APIs and critical process materials.
-
New product introductions and tech transfer: Assess site start-up readiness and timelines with respect to new process materials.
Provide support in defining and maintaining MSAT processes as part of tech-transfer activities:
-
Maintain procedures, templates and forms
-
Ensure standardization and efficiency across processes
-
Collect feedback from program managers and subject matter experts to improve and simplify the processes
Regulatory and quality interfaces:
-
Support internal/external audits and regulatory authority inspections; present risk assessments, process impurities control strategies, and evidence of effectiveness.
Cross-functional leadership:
-
Collaborate and find opportunities to harmonize approaches, create synergies and contribute to the development of Raw Materials Center of Excellence.
Minimum qualifications, skills and competencies
-
MS in Chemical Engineering, Chemistry, Pharmaceutical Sciences, or related field.
-
5+ years (Scientist/Engineer) in MSAT, Process Development, Quality, or related GMP manufacturing role in pharma/biotech.
-
Hands-on experience performing and defending drug product risk assessments (e.g. ICH Q3C and Q3D assessments)
-
Demonstrated knowledge of raw material/process material qualification and specification setting in a GMP environment.
-
Strong knowledge of cGMPs and ICH guidelines (Q3 series, Q7, Q8, Q9, Q10; for biologics also Q11), BPOG, USP <665>/<1663>/<1664>) and materials of construction.
-
Experience with supplier technical management and dual-source/alternate material qualification.
-
Clear technical writing and presentation skills; ability to communicate complex rationales to regulators and auditors.
-
Bilingual French, English
Working conditions
-
On-site or hybrid; ability to spend time in development and manufacturing areas as needed with PPE and cleanroom gowning as required.
-
Occasional travel to suppliers/CMOs and/or supporting on-site audits (up to ~10%).
If you are ready to actively contribute and join a dynamic sector, please submit your CV via our online form along with a cover letter highlighting your relevant experience and explaining why you are interested in this position.
In case of questions, please reach out to [email protected]
Adragos Pharma is a reliable Contract Development and Manufacturing Organization (CDMO) headquartered in Munich, Germany. We provide comprehensive development and manufacturing services for drug products, including sterile and non-sterile liquids, solids, and semi-solids. Our expertise also covers biologicals, orphan drugs, clinical trials, fill-and-finish, and lyophilization, offering end-to-end solutions from product development to commercial supply.
With production sites in Germany, France, Greece, Norway, Japan, and Switzerland, we ensure high-quality manufacturing across all stages of the drug development process.
Founded in 2020, Adragos Pharma has rapidly grown through an ambitious buy & build strategy, supported by FSN Capital. With a team of over 900 professionals, we are expanding our operations across Europe, North America, and Japan to become a global leader in the CDMO sector.
As a key player in the pharmaceutical industry, CDMOs like Adragos produce 25% of all drugs globally, ensuring access to essential medications. With increasing healthcare demands, we continue to innovate and set new standards in drug manufacturing.
You want to be part of our dynamic growth? Then apply now!
